Educational Tools for Your Clinical Practice
Allergy & ImmunologyAlana Bowman2024-10-15T15:01:57+00:00
Food Allergies
- FARE (Food Allergy Research & Education) Resources
- Common Allergens
- Understanding Food Labels
- It’s a Disease, Not a Diet: A documentary about life with food allergies
- Children With Food Allergies
- Living with Food Allergies: Preparing for College
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab Prescribing Information
- Peanut Oral Immunotherapy Prescribing Information
- Clinical Burden of Food Allergies: Insights from the FARE Patient Registry
- Mental Health Burden of Food Allergies: Insights from Patients and Their Caregivers from FARE Patient Registry
- Food Allergies: National Institute of Allergy and Infectious Diseases
- Food Allergy Information from the American College of Allergy, Asthma & Immunology
- Kids With Food Allergies
- FARE powered by Sifter Shopping Tool for Food Allergy Needs
- Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi-targeted approach
- FDA: Food Allergies
- Managing food allergy: GA2LEN guideline 2022
Asthma
- Dupilumab Prescribing Information
- Tezepelumab Prescribing Information
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
- 2022 GINA Pocket Guide for Asthma Management and Prevention (for Adults and Children Older Than 5 Years)
- 2022 GINA Main Report: Global Strategy for Asthma Management and Prevention
- American Lung Association: Severe Asthma
- Advances and recent developments in asthma in 2020
- Asthma biologics: Comparing trial designs, patient cohorts and study results
- Mepolizumab Prescribing Information
- National Jewish Health Inhaler Instructional Videos
Chronic Spontaneous Urticaria (CSU)
- Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
- Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
- Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)
- Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
- Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
- Urticaria
- Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial
- Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
- Dupilumab Efficacy In Patients With Chronic Spontaneous Urticaria By Ige Level: Liberty-CSU Cupid Study A
- Novel biologics for treatment of chronic spontaneous urticaria
- Dupilumab: A Review of Present Indications and Off-Label Uses
- Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
- Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
- Total IgE as a Marker for Chronic Spontaneous Urticaria
- Chronic Idiopathic Urticaria
- Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
- The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
- Patient education: Hives (urticaria) (Beyond the Basics)
CardiologyAlana Bowman2024-11-14T15:27:06+00:00
Acute Coronary Syndrome
- Acute Myocardial Infarction Toolkit
- Heart Disease: Resources for Individuals and Patients
- Acute coronary syndromes
- 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Atherothrombosis
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
- Coagulation factor Xa (recombinant), inactivated-zhzo Prescribing Information
- 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee
- Management of bleeding in patients receiving direct oral anticoagulants
Cardiac Imaging
- 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
- Selecting the optimal cardiac stress test
Dyslipidemia
- Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
- An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
- ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
- HPS3/TIMI55-REVEAL: Long-term Safety and Efficacy of Anacetrapib
- ROSE Study: Obicetrapib and High-Intensity Statin Therapy
- Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
- Bempedoic Acid for LDL-C Lowering: What Do We Know?
- Heart Disease and Stroke Statistics—2021 Update
- Identification of female-specific risk enhancers throughout the lifespan of women to improve CVD prevention
- Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
- Prescribing Information for Alirocumab
- ACC Statin Intolerance Tool
- Cholesterol Tools and Resources
Familial Chylomicronemia Syndrome (FCS)
- Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
- Understanding FCS – for Patients
- About FCS
- 2015-2020 Dietary Guidelines
Familial Hypercholesterolemia (FH)
- Diagnostic Criteria for Familial Hypercholesterolemia
- Familial Hypercholesterolemia: Cardiovascular Risk Stratification and Clinical Management
Heart Failure (HF)
- Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
- Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
- Heart Failure: Patient Education
Hypertension
- CDC Facts About Hypertension
- Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparison, Reflections, and Recommendations
- High Blood Pressure Information for Patients
- Treatment of resistant hypertension
- Million Hearts® Hypertension Control: Action Steps for Clinicians
Hypertriglyceridemia
- Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
- REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. AHA 2018.
- Fish and Omega-3 Fatty Acids
Hypertrophic Cardiomyopathy (HCM)
- Provider Tools: AHA HCM Educational Resources
- Partnership Between Primary Care and Centers of Excellence for HCM
- Provider Tools: Genetic Testing and Counseling for HCM
- Systematic Review of Current Diagnostic and Treatment Methods for HCM
- Talking With Patients About Hypertrophic Cardiomyopathy
- 2024 AHA/ACC/Multisociety Guideline for the Management of HCM
- Mavacamten Prescribing Information
- Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
- Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Risk Stratification in HCM
- Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
- Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy
- Patient Information: Hypertrophic Cardiomyopathy (HCM)
- Hypertrophic Cardiomyopathy Association (HCMA)
- Patient Information: Hypertrophic Cardiomyopathy (HCM)
- Encouraging Shared Decision Making in HCM
- Patient Info: HCM Action Plan
- Patient Info: HCM Fact Sheets
- Patient Info: HCM Genetic Testing
- Patient Info: Hypertrophic Cardiomyopathy
Lipoprotein (a) [Lp(a)]
- A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice
- Patient Resource: What is Lipoprotein(a)?
- Patient Resource: Treating High Lp(a)
- Assessing Risk: Infographic on Lp(a) Screening
- Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
- Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease
Venous Thromboembolism (VTE)
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
- Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
- What is Venous Thromboembolism (VTE)?
- Wells’ Criteria for Pulmonary Embolism
DermatologyAlana Bowman2024-10-15T15:08:51+00:00
Alopecia
- National Alopecia Areata Foundation: Patient Resources
- Alopecia Areata: Current Treatments and New Directions
- Janus kinase inhibitors for alopecia areata
- Treatment Options for Alopecia Areata in Children and Adolescents
- Ritlecitinib Prescribing Information
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework
- Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort
Atopic dermatitis
- Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice?
- Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand
- New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
- Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity
- Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema
- Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis
- Atopic hand dermatitis
- Atopic Dermatitis: Diagnosis and Treatment
- Emerging Systemic Treatments for Atopic Dermatitis
- Therapeutic education in atopic dermatitis
- Towards More Shared Decision Making in Dermatology: Development of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments
- Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
- Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase 3 Trial
- Atopic Dermatitis: Patient Materials
Facial Aesthetics
Pemphigus Vulgaris (PV)
- Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect
- Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris
- Pemphigus Vulgaris
Prurigo Nodularis
- Prurigo Nodularis Signs and Symptoms – AAD Patient Resource
- 2022 Prurigo Nodularis Facts, Symptoms, Testing and Treatment – JAMA Patient Resource
- 2022 JAAD Health-related Quality of Life and Economic Burden of Prurigo Nodularis
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (PRIME and PRIME2)
- Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
- Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
- Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
- Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances
- Psychiatric Comorbidity and the Impact of Socioeconomic Status in Prurigo Nodularis
- Immunotargets and Immunotherapy for Prurigo Nodularis
- 2021 United States Expert Panel Consensus on the Diagnosis and Management of Prurigo Nodularis
- Pathophysiology, Diagnosis and Pharmacologic Treatment of Prurigo Nodularis
- Etiology, Clinical Diagnosis, Treatment Planning and Patient Education for Prurigo Nodularis
Psoriasis
- Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
- Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
- Psoriatic Disease Information for Parents/Caregivers
- Treatments for Psoriatic Disease – For Patients
- Understanding Psoriatic Disease – For Patients
- Psoriasis Clinical Guideline from the American Academy of Dermatology
- National Psoriasis Foundation
- Psoriasis Q & A – For Patients
EndocrinologyAlana Bowman2024-10-15T15:12:13+00:00
Diabetes Mellitus
- Diabetes-Related Macular Edema
- CDC Managing Blood Sugar
- AFP Publications: Type 2 Diabetes
- Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison
- The Links Between Sleep Duration, Obesity and Type 2 Diabetes Mellitus
- Obesity Management as a Primary Treatment Goal for Type 2 Diabetes: Time to Reframe the Conversation
- Standards of Medical Care in Diabetes—2022
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
- New Decade, New FDA Guidance for Diabetes Drug Development
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- AACE Diabetes Resource Center
- Diabetic Retinopathy: A Position Statement by the ADA
- Family Practice Management Toolbox: Diabetes
- Diabetes and You: All Medicines Matter!
- Advanced Insulin Management: Using Insulin-to-Carb Ratios and Correction Factors
- Living with Diabetes
Acromegaly
- Acromegaly Patient Information
- A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly
- Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
Osteoporosis
- Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
- Overview of the management of osteoporosis in postmenopausal women
- NIH Handout on Health: Osteoporosis – Patient Handout
Family Practice/Internal MedicineAlana Bowman2024-10-15T15:14:41+00:00
Chronic Cough
- Cough hypersensitivity and chronic cough
- The current and emerging treatment landscape for chronic cough
- Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
- Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
- Healthcare utilization and costs in chronic cough
- Incidence and Prevalence of Cough in a Rural Health System: A 20-Year Study
- Chronic cough: new insights and future prospects
- On Chronic Cough Diagnosis, Classification, and Treatment
- Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
- Understanding the Foundations of Chronic Cough
- American Lung Association: Chronic Cough Resources and Videos
- European Respiratory Society Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children
- Management of chronic refractory cough in adults
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
- P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough
Pain Management
Peyronie’s Disease
- A clinical pathway for the management of Peyronie’s disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association
- JAMA Patient Page: Peyronie’s Disease
- Peyronie’s Disease
- Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction
Substance Use Disorders
- NIH/National Institute on Drug Abuse – Patient Information
- Sublocade Prescribing Information
- Medication Assisted Treatment (MAT) Certification
- Substance Abuse & Mental Health Services Administration (SAMHSA) supported CME courses on prescribing opioids for chronic pain from AAAP, AOAAM, ASPMNDPT, ATTC and ASAM
GastroenterologyAlana Bowman2024-11-12T18:17:57+00:00
Biosimilars
- Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases
- Biosimilars – What IBD Patients Should Know
- Biosimilar Patient and Prescriber Outreach Materials
- Biosimilar Development, Review, and Approval
- Biosimilars Basics infographic for Patients
- What is a Biosimilar?
- Prescribing Biosimilar Products
- Biosimilar Development Process
Cirrhosis
- How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study
- Cirrhosis
- Hepatic Encephalopathy
Eosinophilic Esophagitis (EoE)
- Diagnosis and management of eosinophilic esophagitis
- AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
- Disease Burden and Unmet Need in Eosinophilic Esophagitis
- Biologics in Eosinophilic Gastrointestinal Diseases
- Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis
- Treatment of Eosinophilic Esophagitis: Clinical Decision Support Tool
Hepatitis C Virus (HCV)
- AGA Hepatitis C Virus FAQs
- AGA GI Patient Center: Hepatitis C (HCV)
- Direct-Acting Antivirals: Side Effects Management Handouts
- CDC Hepatitis C Resource Center
- U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients
- Direct-Acting Antivirals: Side Effects Management Handouts
- Hepatitis C Guidance 2019 Update: AASLD‐IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Hepatitis B Virus (HBV)
- CDC Patient Education Center: Hepatitis B Virus
- CDC Testing Asian Americans and Pacific Islanders for Hepatitis
- Q&A: HIV links to diminished control of HBV coinfection
- CDC Interpretation of Hepatitis B Serologic Test Results
Inflammatory Bowel Disease (IBD)
- AGA IBD Patient Resources
- Resources For Nurses & Advanced Practice Providers: Crohn’s and Colitis Foundation
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
- Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
- Improving IBD outcomes in the era of many treatment options
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis
- Efficacy and safety of biologics and small molecule drugs for patients with moderate to severe ulcerative colitis: a systematic review and network meta-analysis
Crohn’s and Colitis Foundation Resources for Patients
- Crohn’s & Colitis Foundation. Free educational brochures
- Treatment Approaches in IBD: Shared Decision-Making
- Ostomy Tips and Tricks
- Living with Crohn’s Disease
- Living with Ulcerative Colitis
- CCF IBD Medication Guide
- UIcerative Colitis 101
- Crohn’s 101
Crohn’s and Colitis Foundation Resources for Clinicians:
- Inflammatory Bowel Diseases Clinical Primer and Care Pathway Tool Kit
- IBD Nurse & Advanced Practice Provider Best Practices Resource Library
- Appeal Letters
Lysosomal Acid Lipase Deficiency (LAL-D)
- Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group
- Lysosomal Acid Lipase Deficiency (LALD) – Patient Information
Non-Alcoholic Fatty Liver Disease (NAFLD)
- Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease
- The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
- NAFLD: Differential Diagnosis – Summary
- NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency
Hematology-OncologyAlana Bowman2024-11-08T17:08:29+00:00
Biosimilars
- Use of Biosimilar Medications in Oncology
- NCCN Guidelines for the Use of Biosimilars
- Biosimilar and Interchangeable Biologics: More Treatment Choices
- FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
- Biosimilar Product Information
Bladder Cancer
- Bladder Cancer Treatment (PDQ®)–Health Professional Version
- Immunotherapy for Bladder Cancer – American Cancer Society
- Bladder Cancer – Nation Cancer Institute – For Patients
- Bladder Cancer – Nation Cancer Institute – For Providers
Breast Cancer
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- Breast Cancer Treatment – Patient Information
- National Cancer Institute: Breast (Patient Version)
- National Cancer Institute: Breast (Health Professional Version)
- American Society of Clinical Oncology Breast Cancer Guidelines
Colorectal Cancer (CRC)
- Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
- American Society of Clinical Oncology Gastrointestinal Cancer Guidelines
- US Preventive Services Task Force Colorectal Cancer: Screening—Final Recommendation Statement
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- NCCN Guidelines for Colon Cancer
- NCCN Guidelines for Rectal Cancer
- Colorectal Cancer Alliance: What are NTRK fusions?
- Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
- When should we order a next generation sequencing test in a patient with cancer?
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
- Colorectal Cancer Screening: What Are My Options?
- National Cancer Institute: Colorectal Cancer [patient version]
- National Cancer Institute: Colorectal Cancer [health professional version]
- National Cancer Institute: Drugs Approved for Colon and Rectal Cancer
General Hematology/Oncology
- Agency for Healthcare Research and Quality Technology Assessment Program. Role of Liquid Biopsy in Detection and Management of Cancer in the Medicare Population
- ASCO Supportive Care and Treatment Related Issues
- Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
- NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines for Patients
- Increasing Cancer Screening Rates in Primary Care
- Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
- CDC Recommended Screening Tests for Cancer
- USPSTF Lung Cancer Screening Recommendations: 2021 Updates
- American Cancer Society Guidelines for the Early Detection of Cancer
- American Cancer Society guideline for diet and physical activity for cancer prevention
Hematologic Malignancies
- Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
- Proteasome Inhibitors for the Treatment of Multiple Myeloma
- Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics
- Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
- Carfilzomib, dexamethasone, and daratumumab for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
- Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
- Multiple Myeloma Disease Overview
- Multiple Myeloma – Treatment Overview for Patients and Caregivers
- Treatment for Multiple Myeloma – for Health Professionals
- National Cancer Institute: Leukemia (Patient Version)
- National Cancer Institute: Leukemia (Health Professional Version)
- National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Patient Version)
- National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Health Professional Version)
- NCCN CLL Guidelines for Patients
- Leukemia & Lymphoma Society Patient Information Booklets
- American Society of Clinical Oncology Hematologic Malignancies Guidelines
- Multiple Myeloma Research Foundation Patient Resources
Hematologic Malignancies and Disorders: Alpha Thalassemia
- Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia
- Advances in the management of α -thalassemia major: reasons to be optimistic
- Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study
- Alpha-Thalassemia
- What is Thalassemia?
Hematologic Malignancies and Disorders: B-cell Lymphomas
- Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- NCCN Guidelines for Patients: Mantle Cell Lymphoma
- NCCN Guidelines for Patients: Follicular Lymphoma
- NCCN Guidelines for Patients: DLBCL
- NCCN Clinical Practice Guidelines. B-Cell Lymphomas. Version 5.2022
- American Society of Clinical Oncology Hematologic Malignancies Guidelines
- Leukemia & Lymphoma Society Patient Information Booklets
Hematologic Malignancies and Disorders: Chronic Lymphocytic Leukemia (CLL)
- CLL Guide: Information for Patients and Caregivers
- NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
- NCCN Guidelines: Chronic Lymphocytic Leukemia for Patients
Hematologic Malignancies and Disorders: Multiple Myeloma
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
- Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
- Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
- Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial
- Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
- KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
- “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
- Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
- The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
- Risk Evaluation and Mitigation Strategy (REMS) Document BLENREP (belantamab mafodotin) REMS Program
- Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
- Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
- Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Hematologic Malignancies and Disorders: Myelodysplastic Syndromes (MDS)
- NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
- Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
- About Myelodysplastic Syndromes (MDS)
- Myelodysplastic Syndromes
- Treating MDS Toolkit
- The Diagnostic Spectrum of MDS, MDS/MPN, and MF Reference Card
- What is MDS? iPad App
Hemophilia
- World Federation of Hemophilia Guidelines for the Management of Hemophilia
- National Hemophilia Foundation Recommendations for Genotyping for Persons with Hemophilia
- Impact of novel hemophilia therapies around the world
- Centers for Disease Control and Prevention: Hemophilia Homepage
- National Hemophilia Foundation: Hemophilia A
- World Federation of Hemophilia: Guidelines for the Management of Hemophilia, 3rd Edition
Hepatocellular carcinoma
- National Cancer Institute: Liver and Bile Duct Cancers (Patient Version)
- National Cancer Institute: Liver and Bile Duct Cancers (Health Professional Version)
Kidney Cancer
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
- Kidney Cancer – American Cancer Society
- Kidney Cancer – NIH – Patient Resources
Lung Cancer
- American Cancer Society Lung Cancer – Patient Information
- American Cancer Society Questions to Ask About Lung Cancer
- US Preventive Services Task Force Lung Cancer: Screening
- Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- National Cancer Institute: Lung Cancer (Patient Version)
- National Cancer Institute: Lung Cancer (Health Professional Version)
- National Comprehensive Cancer Network (NCCN) Guidelines for Treatment of Cancer by Site
- IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
Melanoma
- Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial
- Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
- Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115
- American Cancer Society: Immunotherapy for Melanoma Skin Cancer
- SITC Patient Resources: Melanoma and Other Skin Cancers
- Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
- Adjuvant immunotherapy for melanoma patients: progress and opportunities
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
- Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
- Clinical updates in neoadjuvant immunotherapy for melanoma before surgery
- Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
- The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
- Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
- NCI: Oncolytic Virus Enables the Immune System to Attack Tumors Subscribe
- Oncolytic virotherapy: basic principles, recent advances and future directions
- Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
- Oncolytic viruses in melanoma
- Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study
- Melanoma Research Alliance: T-VEC
- Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
- What Screening Tests Are There?
- NCCN Guidelines for Patients: Melanoma
- NCCN Clinical Practice Guidelines in Oncology – Cutaneous Melanoma
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
- Pathological response and survival with neoadjuvant therapy in melanoma
- The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
- Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
- Atezolizumab Prescribing Information
- Cobimetinib Prescribing Information
- Vemurafenib Prescribing Information
- Melanoma Treatment – for health professionals
- Melanoma Risk Assessment Tool
- Combination Therapy: Nivolumab + Ipilimumab
- Immunotherapy for Melanoma Skin Cancer
- Targeted Therapy for Melanoma
- The Skin Cancer Foundation: Skin Cancer 101 for Patients
Ovarian Cancer
- SGO Gynecologic Cancer Resources For Patients And Their Families
- ACOG Ovarian Cancer FAQs
- Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
- ASCO Guidelines: PARP Inhibitors in the Management of Ovarian Cancer—Rapid Update
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
- Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
- National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Patient Version)
- National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Health Professional Version)
Uveal Melanoma
- Tebentafusp-tebn Prescribing Information
- National Comprehensive Cancer Network, NCCN Guidelines Melanoma: Uveal. Version 2.2021
- Intraocular (Uveal) Melanoma Treatment (PDQ®): Patient Version
- The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
- Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
- Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis
Infectious DiseaseAlana Bowman2024-10-15T15:43:04+00:00
Coronavirus (COVID-19)
- Ritonavir-Boosted Nirmatrelvir Prescribing Information
- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Medications
- The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
- The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
- Vaccines and therapeutics for immunocompromised patients with COVID-19
- Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
- The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era
- Long COVID: major findings, mechanisms and recommendations
- Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
- The COVID-19 Pandemic Rages on for People Who Are Immunocompromised
- CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
- IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
- COVID-19 Drug Interactions
- Dexamethasone in Hospitalized Patients with Covid-19
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- NIH COVID-19 Treatment Guidelines
- FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
- Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)
- CDC Coronavirus Disease 2019 (COVID-19) Resources
- WHO Resources: COVID-19 Pandemic
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- JAMA Patient Page: Oral antiviral medications for COVID-19
- Molnupiravir EUA
- Nirmatrelvir EUA
Gram-negative Bacterial Infections
- Gram-negative Bacteria Infections in Healthcare Settings
- IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- New Perspectives on Antimicrobial Agents: Cefiderocol
Cytomegalovirus (CMV)
- Letermovir for Secondary Prophylaxis of CMV Infection
- Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
- Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
- Cytomegalovirus (CMV) Infection
- About CMV for Patients
- Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients
Herpes Zoster
HIV
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
- INSTI Drug Interactions
- HIV and Drug-resistance Testing
- Evidence-based Interventions to Improve HIV Medication Adherence
- Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
- Adherence to the Continuum of Care
- Drug-Drug Interactions
- Drug Database: Cabotegravir
- Women with HIV
- Adverse Effects of Antiretroviral Therapy
- Considerations for Antiretroviral Therapy in the Older Patient
- Stanford University HIV Drug Resistance Database
- Understanding HIV Laboratory Tests – for Patients
- NNRTI Drug Interactions
- NRTI Drug Interactions
- PI Drug Interactions
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
- What to Start: Selecting a First HIV Regimen
PrEP
- Patient/Clinician Handout: PrEP 2-1-1
- HIV PrEP With FTC/TDF Among Cisgender Women
- Equity of Prep Uptake by Race, Ethnicity, Sex, and Region in the US in the First Decade of Prep
- Characteristics Associated with PrEP Discussion and Use Among Transgender Women Without HIV Infection – National HIV Behavioral Surveillance
- Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
- Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection
- PrEP Resources in all 50 States
- National Clinician Consultation Center for PrEP
- Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update
- Quick Guide: 2021 PrEP Update
- Pre-Exposure Prophylaxis (PrEP)
- HIV Prevention Materials for Your Practice
- Let’s Stop HIV Together: HIV Prevention
- Drug information on cabotegravir
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
- Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084
Influenza
- A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season – ScienceDirect
- Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
- Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
- Seasonal Influenza Vaccine Effectiveness Studies
- Influenza Antiviral Medications: Summary for Clinicians
- FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
- Information for Clinicians on Influenza Virus Testing
- What You Should Know About Influenza (Flu) Antiviral Drugs
- People at High Risk For Flu Complications
- Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
- Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial
- Similarities and Differences between Flu and COVID-19
Invasive Fungal Infections
- CDC Fungal Diseases – Patient Information
- Information for Healthcare Professionals about Invasive Candidiasis
- Information for Healthcare Professionals about Mucormycosis
- Information for Healthcare Professionals about Aspergillosis
Molecular Diagnostics
- Panels and Syndromic Testing in Clinical Microbiology
- Advances in rapid diagnostics for bloodstream infections
- Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis
- Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables
- Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel
Pediatrics
- Recommendations for Prevention and Control of Influenza in Children, 2022–2023
- Cryptosporidiosis
- Giardiasis
- Swimming Pool Hygiene
- Facts About Crypto and Swimming Pools – Patient Handout
- Human Papillomavirus (HPV): The Need to Immunize – Patient Handout
Pneumococcal Disease
- Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations
- Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children
- Updated ACIP Recommendations and Evidence Review: Use of PCV15 and PCV20 Among US Adults
- Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults
- Pneumococcal Vaccination
- AAFP: Simplifying Pneumococcal Immunizations for Adults
- Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States
- Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
- PneumoRecs VaxAdvisor Mobile App
- Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines
- PCV15 Prescribing Information
- PCV20 Prescribing Information
Respiratory Syncytial Virus (RSV)
- RSV surges early in 2022, but appears to make early retreat
- Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season
- Multiple RSV vaccines in late-stage development show promise in older adults
- CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine
- Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
- A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
- Respiratory Syncytial Virus (RSV)
- CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions
- Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
- Respiratory Syncytial Virus Infection
NephrologyAlana Bowman2024-10-15T14:50:47+00:00
Chronic Kidney Disease (CKD)
- Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
- Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
- Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
- Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
- Roxadustat for CKD-related Anemia in Non-dialysis Patients
- Anemia in Chronic Kidney Disease
- FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis
NeurologyAlana Bowman2024-10-15T15:48:13+00:00
Alzheimer’s Disease
- Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
- Alzheimer’s Disease Facts and Figures 2024
- Focusing on earlier diagnosis of Alzheimer’s disease
- For Patients: Treatments for Alzheimer’s
- Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
- Alzheimer’s disease drug development pipeline
- Treatment with GLP-1 RAs and incidence of dementia
- Donanemab in Early Symptomatic Alzheimer Disease
- Alzforum: news and information dedicated to Alzheimer’s disease
Amyotrophic Lateral Sclerosis
Migraine
- Frequently Asked Questions About Migraine Symptoms
- Atogepant for the Preventive Treatment of Migraine
Multiple Sclerosis (MS)
- Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs)
- MS, COVID-19 and vaccines – updated global advice
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
- Aging and efficacy of disease-modifyingtherapies in multiple sclerosis: a meta-analysis of clinical trials
- Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
- BEACON: BEtaferon prospective study on Adherence, COping and Nurse support): Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b
- Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS
- Adherence — Patient Information
- Resources for You and Your Practice
- Mobile Applications for People with Multiple Sclerosis (MS)
- Family Planning and Pregnancy With Multiple Sclerosis
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
- Disease-modifying Therapies for MS
Parkinson’s Disease
Stroke
- Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial
- Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke
- Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines
- Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
- Signs and Symptoms of a Stroke
- Recognize Warning Signs of a Stroke (Act FAST)
- Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke
- American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention
- REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
ObesityAlana Bowman2024-10-15T15:00:17+00:00
- Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
- Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
- Patient Resource: Your Obesity Care Team
- Internet Tracking Tools for the Bariatric Patient
- CDC: Healthy Weight, Nutrition, and Physical Activity—Planning Meals
- Who’s Who on the Obesity Care Team – Patient Education
- 2023 Consensus Statement on Obesity
- Curated Resources for the Management of Obesity in the Primary Care Setting
- Guide for the Management of Obesity in the Primary Care Setting
- Prescription Medications to Treat Overweight and Obesity
- Bariatric Surgery: Patient Materials
- STOP Obesity Alliance – WHY WEIGHT? A Guide to Discussing Obesity & Health with Your Patients
- American Board of Obesity Medicine (ABOM)
- How To Use Fruits and Vegetables – Patient Handout
- Rethink Your Drink – Patient Materials
- Childhood Obesity Facts
OphthalmologyAlana Bowman2024-11-08T17:11:14+00:00
Age-Related Macular Degeneration (AMD)
- PULSAR: Intravitreal Aflibercept 8 mg in nAMD: 48-Week Results, Phase 3 Trial
- RGX-314: Gene Therapy for nAMD by Subretinal Delivery: Phase 1/2a Dose Escalation Study
- OPT-302: VEGF-C/D Inhibitor for nAMD: Phase 2b Trial
- OPTIC: Ixoberogene soroparvovec for nAMD: Phase 1 Study
- Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial
- Port delivery system with ranibizumab (Susvimo) recall: What does it mean to the retina specialists
- Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
- Suprachoroidal Delivery of RGX-314 Well-Tolerated in Wet AMD
- FDA approves faricimab for treatment of wet AMD, DME
- TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- YOSEMITE and RHINE Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- Port delivery system: a novel drug delivery platform to treat retinal diseases
- Review of gene therapies for age-related macular degeneration.
- Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES Study: A Randomized Clinical Trial
- Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease
- Faricimab shows efficacy, safety and durability in treatment of wet AMD
- Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records
- Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
- Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
- Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
- Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
- End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
- Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
- Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
- What AREDS means for you?
- Mayo Clinic: Dry Macular Degeneration
- Understanding Your AMD – Patient Handout
- Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration – Patient Handout
- Results from the Phase 3 HAWK and HARRIER Studies
- Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
Cataract and/or Refractive Surgery
- AAO Refractive Surgery Preferred Practice Patterns 2024
- Saving of Time Using a Software-Based versus a Manual Workflow for Toric Intraocular Lens Calculation and Implantation
- Application of artificial intelligence in cataract management: current and future directions
- Latest Development in Extended Depth-of-Focus Intraocular Lenses: An Update
- AAO Cataract in the Adult Eye Preferred Practice Pattern 2021
- Cataract and Refractive Lens Exchange Questionnaire
- Post-Refractive IOL Calculator
- American Society of Cataract and Refractive Surgery
- Physician Quality Reporting System Measures Associated with Cataract Surgery
- Toric IOL Calculator
- Preparing for Cataract Surgery – Postoperative Concerns – Patient Handout
Conjunctivitis
- Conjunctivitis (Pink Eye) Treatment
- Conjunctivitis: What is Pink Eye? – Patient Information
- Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout
Diabetic Macular Edema (DME)
- PHOTON: Intravitreal Aflibercept 8 mg in DME: 48-Week Results, Phase 2/3 Trial
- KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema
- Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
- A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema: The European DME Registry Study
- Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study
- The Mechanism of the Bispecific Antibody Faricimab
- Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
- Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout
- Facts About Macular Edema
- 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study
- Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
- Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis
- Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States
Diabetic Retinopathy
- Retina Summary Benchmarks, 2023 (for Patients)
- Understanding Diabetic Retinopathy – Patient Handout
- Diabetic Retinopathy Clinical Research Network Publications
- Diabetic Retinopathy: Causes, Symptoms, Treatment
- PANORAMA: Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy
- Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
- Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy
Geographic Atrophy
- OAKS/DERBY: Pegcetacoplan for GA Secondary to AMD: Phase 3 Trials
- GATHER2: Avacincaptad pegol for GA: Phase 3 Trial
- Understanding Geographic Atrophy in Advanced Non-Exudative Age-Related Macular Degeneration: a Teaching Case Report
- Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
- Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
- Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
- Prevalence and phenotype associations of complement factor I mutations in geographic atrophy
- Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study
- Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
- Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial
General
- ICD-10-CM for Ophthalmology
- EyeNet Magazine
- National Institutes of Health Guidelines on Human Subjects Research
- AAO Preferred Practice Patterns
- American Academy of Ophthalmology. Teleophthalmology: how to get started.
- Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet.
- Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
- AAO.org: Home Eye Test for Adults
Glaucoma
- CDC Vision Health Initiative: Facts About Glaucoma
- Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
- The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
- A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
- Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
- National Eye Institute: Glaucoma
- Advances in medical therapy for glaucoma
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
- Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
- Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
- 2 Year Experience with Latanoprostene Bunod in Clinical Practice
- Sustained-release drug delivery systems for the treatment of glaucoma
- Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
- Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
- Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results
- Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
- Bimatoprost Implant. Prescribing Information
- Microinvasive Glaucoma Surgery (MIGS)
- Xen Gel Stent: Directions for Use
- American Glaucoma Society
- Facts About Glaucoma
Inherited Retinal Diseases
- Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium
- Genetic testing and diagnosis of inherited retinal diseases
- AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2022
- Genetic testing for inherited retinal degenerations: Triumphs and tribulations
- Patient Information – Inherited Retinal Diseases
- Foundation Fighting Blindness
Macular Disorders
- Revised Definitions from the International Classification of Diseases of the Vitreomacular Interface
- Understanding Vitreomacular Traction Syndrome – Patient Handout
- Managing Challenging Macular Holes
Macular Telangiectasia
Neurotrophic Keratitis
- Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
- Cenegermin Prescribing Information
- Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
- Neurotrophic keratopathy: An updated understanding
- Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
- Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
- Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy
- Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
- Neurotrophic keratopathy: current challenges and future prospects
- Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
- Cenegermin: A Review in Neurotrophic Keratitis
Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Recommendations for Eculizumab, Inebilizumab, and Satralizumab
- Contemporary management challenges in seropositive NMOSD
- Guthy Jackson Foundation
- Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
- Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
- AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in NMOSD
- Long-term efficacy and safety of inebilizumab in NMOSD: Analysis of AQP4-IgG seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
- Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder (SAkuraStar)
- Neuromyelitis Optica Spectrum Disorder
- The Sumaira Foundation for NMO
Ocular Surface and Lid Margin Disease
- A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
- Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
- Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
- Racial and Ethnic Disparities in Dry Eye Diagnosis and Care
- Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study
- Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study
- Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
- Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
- AAO EyeWiki: Meibomian Gland Dysfunction (MGD)
- NIH Dry Eye Patient Information
- Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
- Demodex and Eye Disease
- Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial
- A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
- Emerging therapies for dry eye disease
- AAO: Improved Dry Eye Drugs for 2022 and Beyond
- The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares
- New strategies for the management of ocular surface disease in glaucoma patients
- Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
- Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
- Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies
- Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
- Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
- Diseases of Ocular Surface
- Dry Eye: Patient Information
- American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
- American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
- Sjögren’s Syndrome Foundation
Presbyopia
- Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
- In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment
- Review of Presbyopia Treatment with Corneal Inlays and New Developments
- Safety and Efficacy of AGN-190584 in Individuals With Presbyopia The GEMINI 1 Phase 3 Randomized Clinical Trial
- 1.25% Pilocarpine for Presbyopia
- Potential new presbyopia treatments in development
- What Is Presbyopia? (Patient Material)
- A Review of Pharmacological Presbyopia Treatment
- Treatments for presbyopia coming soon
Retinal Vascular Diseases (RVO)
- Relationship Between Nerve Fiber Layer Hemorrhages and Outcomes in Central Retinal Vein Occlusion
- Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study
- Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes
- Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
- Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
- Branch Retinal Vein Occlusion Information for Patients
- Central Retinal Vein Occlusion Information for Patients
- Understanding Your Retinal Vein Occlusion (RVO) – Patient Handout
Thyroid Eye Disease (TED)
- Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
- Teprotumumab-Related Hyperglycemia
- Thyroid Eye Disease: Navigating Diagnosis and Treatment
- Patient Brochures
- Navigating the New Treatment Landscape
- Graves’ Eye Disease: Patient Information from the American Thyroid Association
- Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment OPTIC-X Study
- Future Projections in Thyroid Eye Disease
- Patient Material: Examining the Optics of TED
- Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
- Therapeutic IGF-I receptor inhibition alters fibrocyteimmune phenotype in thyroid-associated ophthalmopathy
- Hearing Dysfunction After Treatment with Teprotumumab for Thyroid Eye Disease
- Teprotumumab for patients with active thyroid eye disease: pooled data analysis, subgroup analyses, andoff-treatment follow-up results
- Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists
- Audiology findings in patients with teprotumumab associated otologic symptoms
- Graves’ Disease: Patient Information
- Teprotumumab for the Treatment of Active Thyroid Eye Disease
Uveitis
- Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE)
- Real-Life Efficacy, Safety, and Use of Dexamethasone Intravitreal Implant in Posterior Segment Inflammation Due to Non-infectious Uveitis (LOUVRE 2 Study)
- Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review
- OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema
- Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis
- Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- Preparing for Your Appointment – Patient Handout
Vitreoretinal Surgery
PediatricsAlana Bowman2024-10-16T14:58:14+00:00Respiratory Syncytial Virus (RSV)
Anesthesia
- Statement on Practice Recommendations for Pediatric Anesthesia
- Sugammadex and recurarization in an infant
- Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study
- Sugammadex: Applications in Pediatric Critical Care
- Smart Tots
Gastroenterology
- Cryptosporidiosis
- Giardiasis
- For Parents: Treating Pediatric Dehydration
- Swimming Pool Hygiene
- Children’s Health
- GI Kids
Psychiatry
Respiratory Syncytial Virus (RSV)
- CDC: FAQs About RSV Immunization with mAb for Children ≤ 19 Months
- JAMA: Trends in Age and Disease Severity in Children Hospitalized With RSV Infection Before and During the COVID-19 Pandemic
- AAP Nirsevimab Administration Visual Guide
- Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
- ACOG RSV Prevention Practice Advisory
- For Healthcare Providers: RSV Prevention Information
- MMWR: ACIP Recommendations for Nirsevimab
- MMWR: ACIP Recommendations for Maternal RSV Vaccine
- Nirsevimab Prescribing Information
- Maternal RSV Vaccine Prescribing Information
- Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE)
- Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
- CDC Recommendations for RSV Prevention
- Phase 3 MELODY: Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
- 2024 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger
- Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
- CDC: RSV Vaccination for Pregnant People
- Patient Brochure: RSV in Infants and Young Children
Vaccine-preventable Diseases: General
Vaccine-preventable Diseases: Influenza
- Flu: A Guide for Parents
- Frequently Asked Influenza (Flu) Questions: 2024-2025 Season
- No More Excuses: You Need a Flu Vaccine
- Make a Strong Influenza Vaccine Recommendation
- Influenza Activity in the United States during the 2023–2024 Season and Composition of the 2024–2025 Influenza Vaccine
- Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
- Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
- A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season – ScienceDirect
- Recommendations for Prevention and Control of Influenza in Children, 2022-2023
- Recommendations for Prevention and Control of Influenza in Children, 2022–2023
Vaccine-preventable Diseases: Human Papillomavirus (HPV)
- HPV vaccine promotion: Snapshot of two health departments during the COVID-19 pandemic
- Understanding primary care physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy
- Top 10 Tips for HPV Vaccination Success
- CDC: ACIP’s HPV Vaccination Recommendations
- CDC: Talking to Parents about HPV Vaccine
- Pediatric Vaccination – Information for Parents
- CDC Resources, Education & References for HPV Vaccination
- Human Papillomavirus Vaccination: ACOG Committee Opinion Vaccination
- HPV Vaccination: What Everyone Should Know
- CDC HPV Vaccine Recommendations
- Standing Order for HPV Vaccine
- Centers for Disease Control and Prevention HPV Vaccine Recommendations
- Recommended Immunization Schedule for Persons Aged 0 Through 18 Years (United States, 2024) – Educational Tool for Clinicians and Nurses
- Why Are Childhood Vaccines So Important? – Educational Tool for Parents
PsychiatryAlana Bowman2024-10-16T15:07:34+00:00
Binge Eating Disorder (BED)
- Definition & Facts for Binge Eating Disorder – NIH Patient Education
- Binge Eating Disorder (BED) – A Comorbid Conundrum
- Binge Eating Disorder Resources
Bipolar Disorder
- Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial
- Evaluating lurasidone as a treatment option for bipolar disorder
- Bipolar Disorder Diagnosis and Treatment for Patients
Depression
- National Alliance on Mental Health (NAMI) – Depression
- NIH Information and Resources on Depression (Including Perinatal Depression)
- U.S Preventive Services Task Force: Perinatal Depression – Preventive Interventions
- CDC Patient Information and Resources: Depression During and After Pregnancy
- Feeling sad after your baby is born? Video from the American Academy of Pediatrics
- Perinatal depression: A review
- Development of neuroactive steroids for the treatment of postpartum depression
- Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
- Brexanolone Prescribing Information
- Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
- GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors
- Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program
- Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial
- Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
- Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression
- Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
- BPRS Brief Psychiatric Rating Scale
- PHQ-9 Quick Depression Assessment
- Montgomery-Asberg Depression Rating Scale
- Edinburgh Postnatal Depression Scale
- Depression – stopping your medicine – Patient Handout
- Major Depressive Disorder – Patient Handout
- What are the Causes of Depression? – Patient Handout
Parkinson’s Disease Psychosis
- QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review
- Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment
Schizophrenia
- Schizophrenia educational resources
- Emerging Treatments in Schizophrenia
- Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
- Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities
- Xanomeline–Trospium for Schizophrenia
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- Support Groups and Supportive Resources – Patient Handout
- Approach to Schizophrenia Management At-A-Glance – Patient Handout
- Schizophrenia: Recognizing the Symptoms and Getting Treatment – Patient Handout
Substance Use Disorders
- Providers’ Clinical Support System for Opioid Therapies (PCSS-O): Educational Resources
- Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
- Opioid Treatment Program (OTP) Certification
- Medication Assisted Treatment (MAT) Certification
Tardive Dyskinesia (TD)
PulmonologyAlana Bowman2024-10-16T15:15:05+00:00
Interstitial Lung Disease (ILD)
- PH-ILD Patient Resources
- Pulmonary Fibrosis Foundation Educational Resources
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study
- The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung DiseaseDilemmas in Diagnosis and the Conundrum of Treatment
- Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment
- Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium
- Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
- A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis
- Inhaled Treprostinil: Prescribing Information
- Nintedanib Prescribing Information
- Pirfenidone Prescribing Information
- Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
- Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
- Pulmonary Fibrosis Foundation Patient Education Materials
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
- Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
- Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Interstitial Lung Disease (ILD): Sarcoidosis
Non-Tuberculous Mycobacteria
- Learn about NTM Lung Disease
- “INSIGHT” A Patient’s Perspective on NTM
- CDC Clinician Resources on NTM Infection
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
- NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources
Pulmonary Hypertension
- Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcome
- Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
- Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension
- Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study
- Bridging Specialties: ILD Clinician Toolkit
- Pulmonary Fibrosis Foundation: PH-ILD for Patients
- Pulmonary Fibrosis Foundation: PH-ILD for Healthcare providers
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- Pulmonary Hypertension Association: Patient Resources
- PAH Risk Score Calculators
- Clinical application of risk assessment in PAH: Expert center APRN recommendations
- Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives
- American Lung Association PAH Patient Resources
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
- Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?
- Novel and emerging therapies in pulmonary arterial hypertension
RheumatologyAlana Bowman2024-10-16T15:33:02+00:00
General
- Upadacitinib Prescribing Information
- Risankizumab Prescribing Information
- Guselkumab Prescribing Information
- ACR COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
Biosimilars
- Biosimilars: More Treatment Options Are on the Way
- FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
Gout
- ASN Kidney Week 2023 Abstracts
- EULAR 2024 Abstract Book
- ACR Convergence 2024 Abstracts
- Alliance for Gout Awareness Resources
- Gout Patient Education & Resources
- 2020 American College of Rheumatology Guideline for the Management of Gout
- What’s new on the front-line of gout pharmacotherapy?
- A glance into the future of gout
- PROTECT: Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label clinical trial
- RECIPE: Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
- MIRROR RCT: A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
- Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
- Pegloticase in Combination With Methotrexate in PatientsWith Uncontrolled Gout: A Multicenter, Open-label Study(MIRROR)
- Impact of Uncontrolled Gout on Quality of Life and Importance of Open Dialogue With Patients
- Pegloticase Prescribing Information
- Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
- Gout Patient fact Sheet
IgG4-related disease (IgG4-RD)
- 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease
- (ACR) Information on IgG4-Related Disease: What they are, Getting Diagnosed, Treatment Options, and More
- MITIGATE – Phase 3 Clinical Trial: Efficacy and Safety of Inebilizumab in IgG4-Related Disease
Immune-mediated adverse reactions
- Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
- Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Psoriatic Arthritis
- Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
- Psoriatic Arthritis – Disease Primer
- Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
- JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
- Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
- Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Spondyloarthritis
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
- JAK1 selective inhibitors for the treatment of spondyloarthropathies
- Axial spondyloarthritis: new advances in diagnosis and management
- TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases
- From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
- Recognizing Axial Spondyloarthritis: A Guide for Primary Care
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
- JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
- Pain in Axial Spondyloarthritis: More to It Than Just Inflammation
- Spondylitis Association of America: Resources and Support
- Spondyloarthritis Patient Fact Sheet
- What Is Axial Spondyloarthritis (AxSpA)?
- Recommendations for the Treatment of Ankylosing Spondylitis
- Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
- Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Juvenile Idiopathic Arthritis (JIA)
Lupus
- Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
- Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
- Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
- 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
- Lupus Foundation of American Caregiver Toolkit
- Patient Fact Sheet: Lupus
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
- Phase 3 AURORA study of voclosporin versus standard of care in lupus nephritis
- Belimumab prescribing information
- Voclosporin prescribing information
Rheumatoid Arthritis (RA)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- RA and Vaccinations
- The Purple Book for Biosimilars
- RA Overview (for Patients)
- RA Treatment (for Patients)
- FDA Information on Biosimilars (for Patients)
Systemic Sclerosis
- Understanding Scleroderma: National Scleroderma Foundation Patient Education
- 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Vasculitis
ANCA-Associated Vasculitis
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
- ANCA-Associated Vasculitis
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
- Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
- Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
- Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis
- NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis
- National Organization for Rare Disorders: Churg Strauss Syndrome
Giant Cell Arteritis
Women’s HealthAlana Bowman2024-10-16T15:33:50+00:00
Menopause
- Patient Resource: Mobile-friendly “Swiper” Tool
- Menopause Society for Clinicians
- Menopause Society for Women
- Patient Resource: Deciding About Hormone Therapy Use
- Patient Resource: Vaginal Dryness
- Patient Resource: Nonhormone Treatments for Hot Flashes and Night Sweats
- “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society”
- Understanding Attitudes, Beliefs, and Behaviors Surrounding Menopause Transition
- Disparities in Reproductive Aging and Midlife Health between Black and White women: The Study of Women’s Health Across the Nation (SWAN)
- A review of African American women’s experiences in menopause